API | mapatumumab

mapatumumab Report issue

Biologics mAb Experimental

AACT ChEMBL

Active Ingredient History

NOW

Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer. It targets TRAIL-R1, also known as DR4, which is expressed on the surface of many tumor cell types. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
mapatumumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Tumor necrosis factor receptor superfamily member 10A (Homo sapiens) ^UniProt
- Tumor necrosis factor receptor superfamily member 10A (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

hgs-etr1 | mapatumumab | trail-r1 mab | trm-1 | trm-1 hgs-etr1

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Uterine Cervical Neoplasms (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue